Safety of C1-inhibitor for clinical use

Circulation. 2002 Oct 29;106(18):e132; author reply e132. doi: 10.1161/01.cir.0000035928.78148.cb.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Animals
  • Antithrombin III / drug effects
  • Complement Activation / drug effects
  • Complement C1 Inactivator Proteins / adverse effects*
  • Complement C1 Inactivator Proteins / therapeutic use
  • Complement C1 Inhibitor Protein
  • Disease Models, Animal
  • Dogs
  • Dose-Response Relationship, Drug
  • Heart / drug effects
  • Heparin / pharmacology
  • Humans
  • Myocardial Infarction / drug therapy*
  • Myocardial Ischemia / drug therapy
  • Peptide Hydrolases / drug effects
  • Pilot Projects
  • Risk
  • Swine
  • Treatment Outcome

Substances

  • Complement C1 Inactivator Proteins
  • Complement C1 Inhibitor Protein
  • antithrombin III-protease complex
  • Antithrombin III
  • Heparin
  • Peptide Hydrolases